Progress in understanding humoral rejection in kidney transplantation: implications for patient management.
After more than 40 years of clinical renal transplantation, the contribution of humoral immunity to the pathogenesis of allograft rejection is progressively being clarified. With the advent of a new generation of immunosuppressive agents, the production and consequences of anti-donor alloantibodies can now be controlled. In the upcoming years, immunosuppressive regimens that will specifically control both T- and B-cell responses may further improve long-term allograft survival, if the immunosuppressive efficacy of such regimens is not hampered by an increase in infectious, neoplastic or cardio-vascular complications.